The methamphetamine problem in the United States - PubMed (original) (raw)
Review
The methamphetamine problem in the United States
Rachel Gonzales et al. Annu Rev Public Health. 2010.
Abstract
Significant public health problems associated with methamphetamine (MA) production and use in the United States have emerged over the past 25 years; however, there has been considerable controversy about the size of the problem. Epidemiological indicators have provided a mixed picture. National surveys of the adult U.S. population and school-based populations have consistently been used to support the position that MA use is a relatively minor concern. However, many other data sources, including law-enforcement groups, welfare agencies, substance abuse treatment program admissions, criminal justice agencies, and state/county executives indicate that MA is a very significant public health problem for many communities throughout much of the country. In this article, we describe (a) the historical underpinnings of the MA problem, (b) epidemiological trends in MA use, (c) key subgroups at risk for MA problems, (d) the health and social factors associated with MA use, (e) interventions available for addressing the MA problem, and (f) lessons learned from past efforts addressing the MA problem.
Figures
Figure 1
U.S. Treatment Admissions for Primary Methamphetamine Abuse Source: SAMHSA, Treatment Episode Data Set, 2009
Similar articles
- Methamphetamine abuse: issues for special populations.
Freese TE, Obert J, Dickow A, Cohen J, Lord RH. Freese TE, et al. J Psychoactive Drugs. 2000 Apr-Jun;32(2):177-82. doi: 10.1080/02791072.2000.10400226. J Psychoactive Drugs. 2000. PMID: 10908005 - Criminal justice itreatment admissions for methamphetamine use in California: a focus on Proposition 36.
Anglin MD, Urada D, Brecht ML, Hawken A, Rawson R, Longshore D. Anglin MD, et al. J Psychoactive Drugs. 2007 Nov;Suppl 4:367-81. doi: 10.1080/02791072.2007.10399898. J Psychoactive Drugs. 2007. PMID: 18284103 - Crime Control Act of 1990 [29 November 1990]. [Summary].
United States. United States. Digest Public Gen Bills. 1990;101 Pt 2(1):357-64. Digest Public Gen Bills. 1990. PMID: 12177848 - Risk factors for methamphetamine use in youth: a systematic review.
Russell K, Dryden DM, Liang Y, Friesen C, O'Gorman K, Durec T, Wild TC, Klassen TP. Russell K, et al. BMC Pediatr. 2008 Oct 28;8:48. doi: 10.1186/1471-2431-8-48. BMC Pediatr. 2008. PMID: 18957076 Free PMC article. Review. - Quite a lot of smoke but very limited fire--the use of methamphetamine in Europe.
Griffiths P, Mravcik V, Lopez D, Klempova D. Griffiths P, et al. Drug Alcohol Rev. 2008 May;27(3):236-42. doi: 10.1080/09595230801932588. Drug Alcohol Rev. 2008. PMID: 18368604 Review.
Cited by
- Symptomatic Exposures Among California Inmates 2011-2013.
Butterfield M, Al-Abri S, Huntington S, Carlson T, Geller RJ, Olson KR. Butterfield M, et al. J Med Toxicol. 2015 Sep;11(3):309-16. doi: 10.1007/s13181-014-0456-6. J Med Toxicol. 2015. PMID: 25526949 Free PMC article. - Methamphetamine increases LPS-mediated expression of IL-8, TNF-α and IL-1β in human macrophages through common signaling pathways.
Liu X, Silverstein PS, Singh V, Shah A, Qureshi N, Kumar A. Liu X, et al. PLoS One. 2012;7(3):e33822. doi: 10.1371/journal.pone.0033822. Epub 2012 Mar 29. PLoS One. 2012. PMID: 22479453 Free PMC article. - Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension.
Charoenpong P, Hall NM, Keller CM, Ram AK, Murnane KS, Goeders NE, Dhillon NK, Walter RE. Charoenpong P, et al. Chest. 2024 Jun;165(6):1518-1533. doi: 10.1016/j.chest.2024.01.014. Epub 2024 Jan 9. Chest. 2024. PMID: 38211700 Review. - Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain.
Patel D, Desai GM, Frases S, Cordero RJ, DeLeon-Rodriguez CM, Eugenin EA, Nosanchuk JD, Martinez LR. Patel D, et al. mBio. 2013 Jul 30;4(4):e00400-13. doi: 10.1128/mBio.00400-13. mBio. 2013. PMID: 23900172 Free PMC article. - Bouncing back: Brain rehabilitation amid opioid and stimulant epidemics.
Stewart JL, May AC, Paulus MP. Stewart JL, et al. Neuroimage Clin. 2019;24:102068. doi: 10.1016/j.nicl.2019.102068. Epub 2019 Nov 5. Neuroimage Clin. 2019. PMID: 31795056 Free PMC article. Review.
References
- Anglin MD. Conversation with M. Douglas Anglin. Addiction. 2006;101(2):169–180. - PubMed
- Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J. Psychoactive Drugs. 2000;32(2):137–142. - PubMed
- Anglin MD, Hser Y-I. Treatment of drug abuse. In: Tonry M, Wilson JQ, editors. Drugs and Crime. Chicago: University of Chicago Press; 1990. pp. 1–36.
- Anglin MD, Urada D, Brecht ML, Hawken A, Rawson R, Longshore D. Criminal justice treatment admissions for methamphetamine use in California: a focus on proposition 36. J. Psychoactive Drugs. 2007;4(SARC Suppl.):367–381. - PubMed
- Bachman JD, Johnston LD, O’Malley PM. Ann Arbor, MI: Survey Research Center, Institute for Social Research, University of Michigan; 2006. Monitoring the Future: Questionnaire Responses from the Nation’s High School Seniors 2006. http://monitoringthefuture.org/datavolumes/2006/2006dv.pdf.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous